Weight & Metabolism
The GLP-1 Question Every Woman Over 50 Is Asking, Answered
Is it too late after menopause? Researchers finally checked, and the answer is encouraging.
Okay, let's talk about it. You've seen the headlines, your sister-in-law brought it up at dinner, and half your book club seems to be on one. GLP-1s are everywhere.
But if you're past menopause, there's a quiet worry underneath all of it: Is it too late for me? Will these even work on a body that's already changed this much?
I love that question, because researchers finally asked it too. In the last year and a half, they went back through the big drug trials and sorted the women by menopause stage. Thousands of women. Three different medications. And the answer is really encouraging. Grab your coffee.
First, what is a GLP-1, anyway?
GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut releases after you eat. It tells your brain you're full, slows down how fast your stomach empties, and helps your body handle blood sugar.
The medications are lab-made versions that last much longer than the hormone your body makes. Here are the names you'll hear most:
Semaglutide (Ozempic, Wegovy) works on the GLP-1 receptor.
Tirzepatide (Mounjaro, Zepbound) works on GLP-1 plus a second gut hormone called GIP.
Retatrutide is still in trials and isn't approved yet. It works on GLP-1, GIP and glucagon, which is why people call it a "triple agonist."
Why does this matter so much after menopause? Many women notice their hunger got louder and their weight moved to their middle once estrogen dropped. Those are exactly the signals these medications act on.
Tirzepatide: about 23% weight loss for postmenopausal women
This is the biggest study on the question so far. Researchers at Weill Cornell went back through the tirzepatide (Zepbound, Mounjaro) trials and looked at 2,542 women by where they were in menopause.
Postmenopausal women on the highest dose lost an average of 23% of their body weight. Women on placebo lost just 3%. That's about 46 pounds for a woman starting at 200.
And their waists? Down 20 centimeters, which is almost 8 inches. Waist size is one of the best everyday clues to that stubborn belly fat we all complain about, so that number made me sit up.
In fact, 97% to 98% of women lost at least 5% of their body weight, compared with about a third of women on placebo.
Here's the part that should put the "too late" worry to rest. Postmenopausal women did almost exactly as well as women who hadn't hit menopause yet:
| Stage | Weight lost on tirzepatide | Waist |
|---|---|---|
| Postmenopause | 23% | −20 cm |
| Perimenopause | 23% | −20 cm |
| Premenopause | 26% | −22 cm |
Semaglutide: nearly 20% for postmenopausal women, plus a heart bonus
In May 2026, Novo Nordisk shared a similar breakdown for semaglutide (Wegovy) at the European Congress on Obesity. It used the higher 7.2 mg dose from the STEP UP trial.
Premenopausal women lost about 22.6% of their body weight.
Perimenopausal women lost about 19.7%.
Postmenopausal women lost about 19.8%.
Waist size dropped by roughly 15% to 17.5% across the groups, which researchers called a sign of major loss of the dangerous fat around your organs.
And here's something that matters a lot for us. Heart disease risk climbs after menopause, and it's the leading cause of death in women. A separate look at the big SELECT heart trial included women who already had heart disease. Semaglutide 2.4 mg lowered their risk of heart attack, stroke and heart-related death by 42% in perimenopausal women and 13% in postmenopausal women, compared with placebo. The researchers noted the difference between those two groups wasn't statistically significant, so don't read too much into the gap.
Could GLP-1s help with hot flashes too?
Okay, this is the part that got me excited, so let me be careful with it.
Some women on GLP-1s say their hot flashes and night sweats eased up. Is there anything to that? A 2026 review of the research found that GLP-1s were linked with weight loss and less belly fat in menopausal women, and a few studies also reported fewer hot flashes. The authors were clear, though, that more research is needed.
The most likely explanation right now is the weight loss itself. Carrying extra weight is linked with more hot flashes, and one study found women who lost at least 10% of their body weight were 56% more likely to be hot-flash-free. Since GLP-1s often get women past that 10% mark, some relief makes sense.
Here's the exciting part: Mayo Clinic is running a real clinical trial testing whether tirzepatide reduces bothersome hot flashes in postmenopausal women. It's small, with about 40 women, and it isn't finished yet. But it's one of the first trials to test this directly, and we'll update you when the results are in.
Until then, GLP-1s are not a hot flash treatment. If hot flashes are your biggest problem, talk with your doctor about options made for that.
The honest fine print
I promised to keep it real, so here are a few things to know about these studies:
They're "post hoc" analyses. The trials weren't designed to compare menopause stages. Researchers sorted the women into groups afterward. That's still useful, but it's not quite as strong as a trial built for the question.
The drug companies paid for them. That's normal for this kind of research, but it's worth knowing.
Postmenopausal women lost a little less than premenopausal women. We're talking about 20% vs. 23% on semaglutide, and 23% vs. 26% on tirzepatide. That's a small gap, and the results are still very large.
Results vary a lot from woman to woman. These are averages. Your results depend on your dose, your health and how well you tolerate the medication.
But the big takeaway is clear. Menopause doesn't make these medications stop working. If you've been worried that it's "too late" for your body, the research says otherwise.
The part nobody puts on the billboard: muscle and bone
When you lose weight, you don't lose only fat. In a STEP 1 substudy, researchers scanned 140 participants (76% of them women) with DEXA, the same scan used for bone density. About 39% of the weight lost on semaglutide was lean mass, not fat.
There's good news mixed in. Fat went down more than muscle, so the proportion of lean mass in the body actually went up by about 3 percentage points. Researchers also note that diet-only weight loss costs a similar share of lean mass. The medication isn't uniquely eating muscle. Losing a lot of weight fast just pulls from everywhere.
For us, though, that matters more. We're already losing muscle and bone faster after menopause because of the drop in estrogen. Large, fast weight loss from any cause tends to nudge bone density down too. Researchers studying this keep pointing to the same few things that protect muscle and bone during weight loss:
Strength training, which came out as the strongest factor in the research
Enough protein
Calcium and vitamin D
A baseline DEXA scan, so you and your doctor can see what's changing
That's one more reason we talk so much about lifting around here.
And what about retatrutide?
You've probably seen this name making the rounds. Here's where things stand.
In May 2026, Eli Lilly released topline results from TRIUMPH-1, its first large Phase 3 obesity trial of retatrutide. The trial included 2,339 adults without diabetes. At 80 weeks, people on the highest dose had lost 28.3% of their body weight on average, compared with 3.9% on placebo. Some participants stayed on through 104 weeks, and that group reached 30.3%. Those are numbers we've only seen with bariatric surgery before.
A few honest caveats:
Retatrutide is not FDA-approved. Lilly is expected to file for approval in late 2026.
These are company-reported topline results, and the full peer-reviewed data is still coming.
Side effects were mostly digestive, as with the other GLP-1 medications. More people stopped taking it at higher doses. Analysts also flagged urinary tract infections as a new safety signal, which is worth knowing given how common UTIs already are after menopause.
We haven't seen results broken out for postmenopausal women yet. We'll update this when we do.
So, what do we do with all this?
Here's how I'd sum it up, friend to friend. GLP-1s work after menopause, in big ways, on the scale and around the waist. There's early research on hot flashes and good heart data for women who already have heart disease. And protecting your muscle and bones while you lose weight is not optional for us.
Menopause doesn't stop these medications from working. Postmenopausal women in the trials lost about 20% of their body weight and nearly 8 inches off their waist, and researchers are even studying whether GLP-1s help with hot flashes. If you want to learn more about if a GLP is right for you,
Sources
Tchang et al., Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program, Obesity (2025), with the abstract also available here
Novo Nordisk: Wegovy weight loss across menopause stages, STEP UP and SELECT post hoc analyses, ECO 2026, with a summary here
Orforglipron by menopausal stage: ATTAIN-1 and ATTAIN-2 post hoc analysis, ADA 2026 (Medical News Today) and Pharmacy Times
Mayo Clinic trial: tirzepatide and menopausal hot flashes (NCT07218445)
STEP 1 body composition substudy abstract (Wilding et al.)
TRIUMPH-1 retatrutide topline results, HCPLive (May 2026) and Pharmaceutical Journal